Mutations in the mitochondrial genome (mtDNA) are detrimental to human health since disrupting mitochondrial function disables high-energy consuming cells like neurons and muscle fibers. Mutations in mtDNA accumulated during natural aging or inherited by children lead to diseases characterized by neuromuscular dysfunction. Currently, there are no treatments or cures for mtDNA disease. We want to identify novel therapeutic targets by discovering biological pathways that can be exploited to ameliorate mtDNA disease. In order to accomplish this goal, we are using a new worm model for mtDNA disease that carries an error-prone allele of
polg-1, the polymerase that replicates the mitochondrial genome. Remarkably, this model exhibits hallmark features of mtDNA disease in humans, which include mtDNA instability, mitochondrial dysfunction, loss of neuromuscular function and a shortened lifespan. The mimicry of mammalian disease progression in the
polg-1 mutant worms make them ideal for discovery experiments. With a small, targeted RNAi screen of 130 genes, the knockdown of 22 genes were identified to rescue mtDNA disease. These genes belong to different biological processes, including the IGF/Insulin signaling (IIS) pathway, mitochondrial unfolded protein response (UPRmt), autophagy and apoptosis. Studies with genetic mutants show that reducing either the IIS pathway and or mitophagy ameliorates mtDNA disease in
polg-1 mutant worms by improving mtDNA copy number, mitochondrial function and tissue function. Furthermore, constitutively activating the UPRmt also improves these phenotypes in the
polg-1 mutants. Currently, we are further dissecting the IIS pathway by studying the gene expression pattern in wildtype, in single mutants (
polg-1,
daf-2,
daf-16), and in the double mutants (
daf-16;
polg-1,
polg-1;
daf-2) to understand the mechanism by which IIS regulates mtDNA disease progression.